Recurrent glioblastoma is an aggressive and malignant form of brain cancer that often returns after initial treatment, posing significant therapeutic challenges. According to Bijalwan, Gaurvi et al., 2024, it accounts for around 10 per 100,000 cases globally. According to the recurrent glioblastoma pipeline analysis by Expert Market Research, the drug development landscape is witnessing a growing focus on targeted therapies, immunotherapies, and innovative delivery systems. Several recurrent glioblastoma therapeutic products are in various stages of development, aiming to improve survival rates. Rising research funding, novel biomarker discovery, and clinical advancements are expected to drive growth in the coming years.
Major companies involved in the recurrent glioblastoma pipeline analysis include Ascletis Pharmaceuticals Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., and others.
Leading drugs currently in the pipeline include L19TNF, NMS-03305293, and others.
The drug pipeline for recurrent glioblastoma is expected to grow due to increased focus on targeted therapies, advancement in immuno-oncology approaches, and rising clinical trials for novel combination treatments.
The Recurrent Glioblastoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into recurrent glioblastoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for recurrent glioblastoma. The recurrent glioblastoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The recurrent glioblastoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with recurrent glioblastoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to recurrent glioblastoma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Recurrent glioblastoma is an aggressive form of brain cancer that reappears after initial treatment. It develops from abnormal glial cells and is characterized by rapid tumor regrowth, often at the original site. Recurrence occurs due to the tumor’s resistance to therapies and its infiltration into surrounding brain tissues, making complete surgical removal and sustained remission extremely challenging.
Recurrent glioblastoma treatment includes surgery, chemotherapy, radiation, and experimental approaches such as targeted radiotherapy and immunotherapy, aiming to control tumor progression and extend survival despite limited curative options. In March 2025, Rhenium Obisbemeda (186RNL), an investigational drug developed by UT Health San Antonio, demonstrated a more than twofold increase in median survival and progression-free time in recurrent glioblastoma patients during a Phase 1 trial. Such results are expected to impact the treatment pipeline positively in the forecast period.
Glioblastoma multiforme (GBM) is a rare, aggressive, and lethal brain tumor that primarily affects older adults. As stated by Bijalwan, Gaurvi et al., 2024, the global prevalence of GBM is around 10 per 100,000 individuals. Tejaswi Kanderi et al., 2024, reported that the annual incidence is approximately 35 per million, with a higher occurrence in males. The incidence significantly rises with age, peaking between 75 to 84 years, and reaching 130 per million among individuals aged 65 years and older.
This section of the report covers the analysis of recurrent glioblastoma drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I, with approximately 52%, covers a major share of the total recurrent glioblastoma clinical trials. This reflects a strong early-stage research activity. Phase II follows with 34.62%, indicating a significant number of candidates progressing toward validation. Early phase I accounts for around 10%. This robust pipeline demonstrates promising advancements that may enhance future treatment options and market growth.
The drug molecule categories covered under the recurrent glioblastoma pipeline analysis include small molecules, monoclonal antibodies, antibody-drug conjugates, immunotherapies, cell-based therapies, and others. The recurrent glioblastoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for recurrent glioblastoma.
Targeted therapy is gaining prominence in the recurrent glioblastoma drug pipeline as a focused treatment approach. For instance, Alpha DaRT (Diffusing Alpha-emitters radiation therapy), which uses radium-224 to deliver localized alpha radiation, is under clinical evaluation for the condition. This method enables precise tumor targeting while minimizing damage to surrounding healthy brain tissue, addressing the challenge of inoperable tumors.
The EMR report for the recurrent glioblastoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed recurrent glioblastoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in recurrent glioblastoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for recurrent glioblastoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of recurrent glioblastoma drug candidates.
L19TNF, sponsored by Philogen S.p.A., is currently undergoing a Phase II trial in combination with lomustine for recurrent glioblastoma. This antibody-cytokine fusion protein delivers TNF directly to tumor sites via the L19 antibody targeting fibronectin. The study is evaluating optimal dosing to maximize clinical benefits while minimizing toxicity across six regimen combinations. Safety, efficacy, and pharmacokinetics are being assessed.
NMS-03305293, developed by Nerviano Medical Sciences, is being evaluated in a Phase I/II trial in combination with temozolomide for recurrent glioblastoma. This PARP inhibitor targets DNA repair mechanisms in cancer cells to enhance cell death. The study is assessing the safety and efficacy of this combination in patients with diffuse gliomas and IDH wild-type glioblastoma at first relapse.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Recurrent Glioblastoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for recurrent glioblastoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into recurrent glioblastoma collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share